Abstract
The existence of long-lasting cellular reservoirs of HIV-1 is one of the major hurdles in developing effective anti-retroviral therapies. These latently infected cells and tissues efficiently evade immune responses and remain dormant until activated, upon which they can generate a productive HIV-1 infection. This classic scenario of viral latency becomes even more difficult to study and model due to the extreme complexity of translating in vivo virus-cell interactions into a controlled in vitro system. The recent developments and constant improvements upon hematopoietic engraftment of human cells and tissues onto recipient immunocompromised murine scaffolds have made it possible to model complex human innate and adaptive immune responses in a small animal model. Specifically, HIV-1 infection has been successfully modeled in these humanized mice to mimic transmission, pathogenesis, host immune responses, and treatment. Here, we review the complexities surrounding modeling HIV-1 latency in vitro and in vivo and highlight the most recent humanized mouse models that support retroviral infection.
Keywords: HIV-1, latency, HAART, humanized mouse model, HIV INFECTIONS, HIV-1 LATENCY, Primary Cells, Transformed cell lines, Small Animal Models, Latent reservoirs
Current HIV Research
Title: Humanized Mouse Models of HIV-1 Latency
Volume: 9 Issue: 8
Author(s): Rachel V. Duyne, Aarthi Narayanan, Kylene K.-Hall, Mohammed Saifuddin, Leonard Shultz and Fatah Kashanchi
Affiliation:
Keywords: HIV-1, latency, HAART, humanized mouse model, HIV INFECTIONS, HIV-1 LATENCY, Primary Cells, Transformed cell lines, Small Animal Models, Latent reservoirs
Abstract: The existence of long-lasting cellular reservoirs of HIV-1 is one of the major hurdles in developing effective anti-retroviral therapies. These latently infected cells and tissues efficiently evade immune responses and remain dormant until activated, upon which they can generate a productive HIV-1 infection. This classic scenario of viral latency becomes even more difficult to study and model due to the extreme complexity of translating in vivo virus-cell interactions into a controlled in vitro system. The recent developments and constant improvements upon hematopoietic engraftment of human cells and tissues onto recipient immunocompromised murine scaffolds have made it possible to model complex human innate and adaptive immune responses in a small animal model. Specifically, HIV-1 infection has been successfully modeled in these humanized mice to mimic transmission, pathogenesis, host immune responses, and treatment. Here, we review the complexities surrounding modeling HIV-1 latency in vitro and in vivo and highlight the most recent humanized mouse models that support retroviral infection.
Export Options
About this article
Cite this article as:
V. Duyne Rachel, Narayanan Aarthi, K.-Hall Kylene, Saifuddin Mohammed, Shultz Leonard and Kashanchi Fatah, Humanized Mouse Models of HIV-1 Latency, Current HIV Research 2011; 9 (8) . https://dx.doi.org/10.2174/157016211798998781
DOI https://dx.doi.org/10.2174/157016211798998781 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Understanding Helicases as a Means of Virus Control
Current Pharmaceutical Design Current Developments in Therapeutic and Diagnostic Strategies for Q Fever: Glimpses of Patent Analysis
Recent Patents on Anti-Infective Drug Discovery Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Drug Targets for Rational Design against Emerging Coronaviruses
Infectious Disorders - Drug Targets Medicinal and Therapeutic Potential of Herbs and Plant Metabolites / Extracts Countering Viral Pathogens - Current Knowledge and Future Prospects
Current Drug Metabolism HIV-1 Induced CNS Dysfunction: Current Overview and Research Priorities
Current HIV Research New Opportunities in the Structure-based Design of Anti-Protozoan Agents
Current Topics in Medicinal Chemistry The Utilization of Gene Targeting Models During in Preclinical Study of Drug Discovery Process - Example of Phenotypic and Functional Analysis of Cacna1 βGene Product
Current Pharmaceutical Biotechnology Applied Proteomics in Companion Animal Medicine
Current Proteomics Basic Approaches in Therapy of Multiple Sclerosis (MS) and Related Diseases: Current Achievement and Prospective
Central Nervous System Agents in Medicinal Chemistry A Coadunation of Biological and Mathematical Perspectives on the Pandemic COVID-19: A Review
Coronaviruses Lipoxin and Synthetic Lipoxin Analogs: An Overview of Anti- Inflammatory Functions and New Concepts in Immunomodulation
Inflammation & Allergy - Drug Targets (Discontinued) Thinking Outside the Brain: Immunorregulation in Multiple Sclerosis
Current Immunology Reviews (Discontinued) Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis
Current Drug Targets Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews Uracils as a Cellular Weapon Against Viruses and Mechanisms of Viral Escape
Current HIV Research Microbiota Regulation of Inflammatory Bowel Disease
Inflammation & Allergy - Drug Targets (Discontinued) Antitumor and Antiviral Activity of Pentacyclic Triterpenes
Mini-Reviews in Organic Chemistry Protein Conformational Pathology in Alzheimers and Other Neurodegenerative Diseases; New Targets for Therapy
Current Alzheimer Research Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases
Inflammation & Allergy - Drug Targets (Discontinued)